I think the product is fantastic and they have substantial partnerships and backing. But AI platforms in healthcare and in particular for stroke are becoming more and more common. I suppose I’m questioning the long term viability of Nico amidst a highly competitive market. I’m pleased to see that they’re hoping to extend to other diagnostic areas, but I suspect they might only be building for acquisition. I’m a medico myself, and the trials at the Royal Melbourne are a positive indicator of its efficacy and potential...but I’m just not entirely sold as yet.
Will consider snapping up some IPO shares, but not without more research. Thanks for all the informative posts here.
